ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO2409

Healthcare Costs Associated with Systemic Lupus Erythematosus (SLE) in the Year Prior to Diagnosis of ESKD: Real-World Evidence from Two Databases in the United States

Session Information

Category: CKD (Non-Dialysis)

  • 2102 CKD (Non-Dialysis): Clinical, Outcomes, and Trials

Authors

  • Bell, Christopher F., GlaxoSmithKline, Research Triangle Park, North Carolina, United States
  • Huang, Shirley, GlaxoSmithKline, Research Triangle Park, North Carolina, United States
  • Guisinger, Amy, GlaxoSmithKline, Research Triangle Park, North Carolina, United States
Background

Approximately 40% of patients with SLE develop lupus nephritis (LN), many of whom may progress to ESKD1; however, data on of the economic burden of ESKD in patients with SLE are scarce. This study described healthcare resource utilization (HCRU) and costs for patients with SLE in the 12 months before ESKD diagnosis in the US.

Methods

This was a retrospective study (GSK Study 215295) of 2 US administrative claims databases (IBM MarketScan [DB#1], Optum Research [DB#2]), conducted from March 1, 2011, to December 31, 2019. Patients were adults with SLE and newly diagnosed ESKD. Study results focus on patients with 12-month continuous enrollment pre ESKD diagnosis reporting on HCRU and costs (2019 US$) during this period.

Results

In total, 1356 (DB#1) and 425 (DB#2) patients with SLE and ESKD were identified (DB#1/DB#2): female 81.8%/79.3%; mean (standard deviation [SD]) age: 46.7 (12.3)/46.3 (14.0) years. Mean (SD) Quan-Charlson Comorbidity Index score in the 12 months pre ESKD was 2.95 (1.9) and 3.05 (2.0) in DB#1 and DB#2, respectively. The mean (SD) healthcare cost in the 12 months pre ESKD was $64,887 (106,822) (DB#1) and $68,219 (137,704) (DB#2) (Table). In the 12-month pre-ESKD period, HCRU was similar across databases and oral corticosteroids were the most commonly prescribed SLE-related medications (Table).

Conclusion

Patients with SLE incur substantial HCRU and costs 1 year before ESKD diagnosis, reflecting the clinical and economic burden of SLE and ESKD.

Reference:
1. Menez SP, et al. Rev Recent Clin Trials 2018;13:105–13

Funding

  • Commercial Support –